Explore the most comprehensive database
1 000 000
bonds
100 000
stocks
175 910
ETF & Funds
100 000
indices
Track your portfolio in the most efficient way
full data on over 1 000 000 bonds, 100 000 stocks, 100 000 indices, 17 000 ETF and 150 000 Mutual Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.
Register
Bond Screener
Amylyx Pharmaceuticals, Q3 2026 Earnings Call Transcript
Amylyx reported positive Phase III LUCIDITY results for avexitide in post-bariatric hypoglycemia: the trial met its primary and all secondary endpoints, showing a 55% reduction in the combined rate of moderate and severe hypoglycemic events versus placebo, with a favorable safety profile. The company is preparing an NDA submission to the FDA by year-end and is investing in commercial infrastructure ahead of a potential 2027 launch of the first approved PBH treatment. Amylyx estimates about 160,000 people in the U.S. live with PBH and says physician engagement reinforces the unmet need, while payer discussions and pricing work are still at an early stage. The company ended September with $768 million in cash after an equity offering. Its pipeline includes AMX0318, with an IND filing targeted for 2027, and AMX0114, now advancing through Phase I dose cohorts in ALS.